Clinical Trial

Disease: Retinitis Pigmentosa, RP, (NCT05805007)

Disease info:

Retinitis pigmentosa (RP) refers to a group of rare inherited retinal dystrophies that cause progressive vision loss due to photoreceptor degeneration and black pigmentation spots on the retinal pigment epithelium. The condition can eventually lead to total blindness after decades.

More than 3,000 mutations in over 60 different genes or loci are known to cause non-syndromic RP. The most common mutations vary by inheritance pattern: RHO gene mutations for autosomal dominant RP, USH2A gene mutations for autosomal recessive RP, and RPGR and RP2 gene mutations for X-linked RP.

The primary symptom is progressive vision loss, typically beginning with night blindness and eventually affecting central vision. Central vision loss may occur at any age due to macular oedema or photoreceptor loss. Additional symptoms include cataracts (severity is age-dependent) and reduced colour vision.

Currently, treatment focuses on slowing disease progression through vitamin A palmitate and lutein-DHA supplementation, oral acetazolamide or topical dorzolamide for cystoid macular oedema, and lens extraction for cataracts that reduce visual acuity. Specialised sunglasses and optical aids can also help manage symptoms.

Frequency:
Retinitis pigmentosa is one of the most common inherited retinal diseases. It is estimated to affect 1 in 3,000 to 1 in 5,000 people.
Official title:
A Single-arm, Open-label Exploratory Clinical Study to Assess the Preliminary Safety of the Gene Editing Drug ZVS203e for the Management of Retinitis Pigmentosa Caused by Mutations in the RHO Gene
Who:

Contact

Name: Liping Yang, MD

Phone: 010-82266595

Email: alexlipingyang@bjmu.edu.cn

Sponsor:

Peking University Third Hospital

Partners:
Locations:
Study start:
Jun. 1, 2023
Enrollment:
9 participants
Gene editing method:
CRISPR-Cas9
Type of edit:
Gene knockout
Gene:
Rhodopsin (RHO)
Delivery method:
Recombinant adeno-associated virus (rAAV) vectors - In-vivo
Indicator
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Active recruiting

Description

The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of ZVS203e administered via subretinal injection in participants with RP caused by RHO site-specific gene mutation (RHO-RP).

Last updated: Jun. 26, 2025
close
Search CRISPR Medicine